As a reminder, our new pick for Thursday is: PLCSF!
This is NOT your typical OTC company:
PLCSF has been selling its primary product in Europe for several years already and recentlyreceived full FDA Approval for pivotal trials in the United States.
The company has seen increasing year-over-year revenue from 2010 - 2012, with 2012 fiscal year revenues reaching over $1M from the company's European sales of RenalGuard®!
The company also recently reported 2013 Q1 revenues of $348k, a gain of over 1,600 percent over the same period a year ago!
PLCSF has a strong patent portfolio in place, and a compelling 'first mover' advantage as RenalGuard® is already gaining market share in Europe, and the company hopes to receive full FDA approval to begin selling their revolutionary product in the United States.
This is a company that did over $1M in revenue in 2012, and yet has an extremely low float, in fact at the current price, the company has an unbelievably tiny marketcap of just over $5M!
Click here for a 'Must-Watch' video from the company's CEO, explaining the current success of RenalGuard® as well an update on the company's clinical trials in the US:
With increasing year-over-year revenues, strong growth in Europe, and the prospect of FDA approval in the United States, this could be an unbelievable year ahead for PLCSF.
Considering the small market cap as well as the strong potential for expansion in the United States, I believe PLCSF could be on track for a breakout 2013!
Begin your research right away and lets be ready for PLCSF this morning as investor awareness on this tiny company is beginning to gain serious momentum. With such a low float, I believe PLCSF could move up the charts rather quickly should momentum take hold!
-James
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
NEW PICK
PLC Systems Inc.
PLCSF
PLCSF Chart
Currently Trading: $0.09
PSP Free Members,
Our new pick is PLCSF!
PLCSF is picking up steam due to a number of recent developments in 2013.
Most notably, the fact that the company already has strong revenue numbers from its European sales of RenalGuard® over the last 3 years.
With U.S. Clinical trials already in place, it could be just a matter of time before PLCSF is on the 'top' of Wall Streets radar!
I believe PLCSF could be one of those plays that could absolutely catch fire in the coming months!
About PLC Systems Inc.
Headquartered in Milford, Mass., PLC Systems Inc. is a medical device company focused on innovative technologies for the cardiac and vascular markets. PLC's newest product, RenalGuard, has been developed to rapidly remove contrast dyes that are potentially toxic to patients undergoing certain cardiac and vascular imaging procedures
Technical Indicators:
PLCSF looks to be on the verge of a significant breakout move up the charts, with a number of technical indicators showing bullish trends developing for the near term.
Already showing upward movement, with a 52 Week High of 30-cents, at current levels, PLCSF remains well below its historic highs to show enormous potential upside in the sessions ahead.
PLCSF has shown consistent growth in both annual revenue and gross profit for the past 3 years, and topping over $1M in total revenue for its latest complete fiscal year ending December of 2012.
I believe we could see significant movement in the sessions ahead with PLCSF, driven by increased media attention surrounding clinical trials and the continued expansion of the company's patent portfolio.
Make sure you begin your research right away and lets be ready for PLCSF this morning as I believe we could see a major breakout to the upside this morning on increasing momentum!
Happy Trading,
-James
This is NOT your typical OTC company:
PLCSF has been selling its primary product in Europe for several years already and recentlyreceived full FDA Approval for pivotal trials in the United States.
The company has seen increasing year-over-year revenue from 2010 - 2012, with 2012 fiscal year revenues reaching over $1M from the company's European sales of RenalGuard®!
The company also recently reported 2013 Q1 revenues of $348k, a gain of over 1,600 percent over the same period a year ago!
PLCSF has a strong patent portfolio in place, and a compelling 'first mover' advantage as RenalGuard® is already gaining market share in Europe, and the company hopes to receive full FDA approval to begin selling their revolutionary product in the United States.
This is a company that did over $1M in revenue in 2012, and yet has an extremely low float, in fact at the current price, the company has an unbelievably tiny marketcap of just over $5M!
Click here for a 'Must-Watch' video from the company's CEO, explaining the current success of RenalGuard® as well an update on the company's clinical trials in the US:
With increasing year-over-year revenues, strong growth in Europe, and the prospect of FDA approval in the United States, this could be an unbelievable year ahead for PLCSF.
Considering the small market cap as well as the strong potential for expansion in the United States, I believe PLCSF could be on track for a breakout 2013!
Begin your research right away and lets be ready for PLCSF this morning as investor awareness on this tiny company is beginning to gain serious momentum. With such a low float, I believe PLCSF could move up the charts rather quickly should momentum take hold!
-James
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
NEW PICK
PLC Systems Inc.
PLCSF
PLCSF Chart
Currently Trading: $0.09
PSP Free Members,
Our new pick is PLCSF!
PLCSF is picking up steam due to a number of recent developments in 2013.
Most notably, the fact that the company already has strong revenue numbers from its European sales of RenalGuard® over the last 3 years.
With U.S. Clinical trials already in place, it could be just a matter of time before PLCSF is on the 'top' of Wall Streets radar!
I believe PLCSF could be one of those plays that could absolutely catch fire in the coming months!
About PLC Systems Inc.
Headquartered in Milford, Mass., PLC Systems Inc. is a medical device company focused on innovative technologies for the cardiac and vascular markets. PLC's newest product, RenalGuard, has been developed to rapidly remove contrast dyes that are potentially toxic to patients undergoing certain cardiac and vascular imaging procedures
Technical Indicators:
PLCSF looks to be on the verge of a significant breakout move up the charts, with a number of technical indicators showing bullish trends developing for the near term.
Already showing upward movement, with a 52 Week High of 30-cents, at current levels, PLCSF remains well below its historic highs to show enormous potential upside in the sessions ahead.
PLCSF has shown consistent growth in both annual revenue and gross profit for the past 3 years, and topping over $1M in total revenue for its latest complete fiscal year ending December of 2012.
I believe we could see significant movement in the sessions ahead with PLCSF, driven by increased media attention surrounding clinical trials and the continued expansion of the company's patent portfolio.
Make sure you begin your research right away and lets be ready for PLCSF this morning as I believe we could see a major breakout to the upside this morning on increasing momentum!
Happy Trading,
-James
RSS Feed